DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Selexipag
Selexipag
Effects of Selexipag and Its Active Metabolite in Contrasting The
Effect of Prostanoids on Human Platelet Function: an Overview
Nanosuspensions of Selexipag: Formulation, Characterization, and in Vitro Evaluation Rusul M
Formulation and Optimization of Lyophilized Selexipag Nanocrystals to Improve the Saturation Solubility and Dissolution Rate
Report on Investigation Results
AHRQ Healthcare Horizon Scanning System – Status Update
Prior Authorization PDL Implementation Schedule
Non-Steroidal Anti-Inflammatories
Queensland Health List of Approved Medicines
Prostacyclin: an Inflammatory Paradox
Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: a Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
UPTRAVI (Selexipag) Is a Selective Non-Prostanoid IP Prostacyclin Receptor Agonist
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low B-Arrestin Recruitment and Desensitization Potential
Recent Advances in Targeting the Prostacyclin Pathway in Pulmonary Arterial Hypertension
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
Extract from the Clinical Evaluation Report for Selexipag
Selexipag / ACT-293987 Pulmonary Arterial Hypertension Protocol AC-065A309
Selexipag: a New Treatment Agent for Pulmonary Arterial Hypertension
Top View
Pdl 10/1/2018
Clinical Use of Extended-Release Oral Treprostinil in the Treatment of Pulmonary Arterial Hypertension
Preferred Drug List Drug Class Review Announcement
Magellan Rx Report
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Interactions with Experimental COVID-19 Therapies
Increased Role of E Prostanoid Receptor-3 in Prostacyclin
Beraprost Modified Release in Addition to Treprostinil for Pulmonary Arterial Hypertension
Preferred Drug List (PDL)
Reimbursement Criteria for Frequently Requested Drugs
Selexipag (Uptravi ) Issued by PHA’S Scientific Leadership Council
Mississippi Division of Medicaid Universal Preferred Drug
USP Category USP Class Example Part D Eligible Drugs* Salt/Ester
USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
Blue Cross and Blue Shield April 2021 Multi-Tier Basic Drug List
Therapeutic Drug Class
Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary 5 Hypertension
EFFECTIVE 01/01/2017 Version 2017.1J
Quantity Limits — Select
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery
Australian Public Assessment Report for Selexipag
CVS Caremark® Value Formulary Effective As of 07/01/2021
CHANGES to the HIGHMARK DRUG FORMULARIES Following Is the Second Quarter 2016 Update to the Highmark Drug Formularies and Pharmaceutical Management Procedures
AHFS Pharmacologic-Therapeutic Classification System
Transition from Intravenous Epoprostenol to Selexipag in Pulmonary Arterial Hypertension: a Word of Caution
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Resubmission
DRAFT COMPARISON of the WHO ATC CLASSIFICATION & Ephmra
【機密性 2】 Report on the Deliberation Results September 14
Interactions with PBC Agents
Emerging Therapies for Pulmonary Arterial Hypertension: a Review of Recently Completed and Ongoing Clinical Trials
Optumrx Quantity Limits
Pulmonary Arterial Hypertension
Uptravi, INN- Selexipag
Contents Editor-In-Chief Dr
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: a Systematic Review and Meta-Analysis
Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report
Letters to the Editors
SELEXIPAG (Uptravi®)
1045 – Rapid Transition from Oral Selexipag to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension
An Oral, Selective Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension